Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort
Authors:
- Franz Felix KonenFranz Felix Konen
- Steffen PfeufferSteffen Pfeuffer
- Konstantin Fritz JendretzkyKonstantin Fritz Jendretzky
- Klaus GehringKlaus Gehring
- Kurt-Wolfram SühsKurt-Wolfram Sühs
- Stephan HalleStephan Halle
- Korbinian BrandKorbinian Brand
- Ralf LichtinghagenRalf Lichtinghagen
- Eline WillemseEline Willemse
- Marc PawlitzkiMarc Pawlitzki
- Jens KuhleJens Kuhle
Open Access
- 4 December 2025
- journal article
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00812
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assayClinica Chimica Acta, 2025
- Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple SclerosisAnnals of Neurology, 2024
- Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisNeurology and Therapy, 2024
- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisJAMA Neurology, 2023
- Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosisNeurological Sciences, 2023
- Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis CentersNeurology and Therapy, 2022
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)European Journal of Immunology, 2021
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsJAMA Neurology, 2020
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisJAMA Neurology, 2019
- Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosisJournal of the Neurological Sciences, 2013